FGFR2 and intrahepatic cholangiocarcinoma: Studies have shown that ICC patients with FGFR2 fusions have longer survival; one such study of 273 ICC patients (83 with FGFR genetic alteration) showed a median OS of 37 versus 20 months for patients with and without FGFR2 mutation/fusion, a difference that persisted even when excluding patients who received FGFR-targeted therapies.